Sinopharm Group
Chinese biotechnology company
From Wikipedia, the free encyclopedia
Sinopharm Group Co., Ltd. is a Chinese pharmaceutical company. The parent company of Sinopharm Group was Sinopharm Industrial Investment, a 51–49 joint venture of state-owned enterprise China National Pharmaceutical Group and civilian-run enterprise Fosun Pharmaceutical.
 logo of Sinopharm Group (same as China National Pharmaceutical Group), with bilingual name on the right | |||||
| Company type | public | ||||
|---|---|---|---|---|---|
| |||||
| ISIN | CNE100000FN7 | ||||
| Industry | Pharmaceutical | ||||
| Founded |
| ||||
| Founder | China National Pharmaceutical Group | ||||
| Headquarters | Sinopharm Plaza, , China | ||||
Area served | China | ||||
Key people |
| ||||
| Revenue |  CN¥227.069 billion (2015) | ||||
| CN¥9.169 billion (2015) | |||||
| CN¥3.761 billion (2015) | |||||
| Total assets | CN¥138.267 billion (2015) | ||||
| Total equity | CN¥30.052 billion (2015) | ||||
| Owner | Sinopharm Industrial Investment (56.79%) | ||||
| Parent | Sinopharm Industrial Investment | ||||
| Subsidiaries | Sinopharm CNMC | ||||
| Footnotes / references in a consolidated basis; equity and profit excluded minority interests; in Hong Kong Financial Reporting Standards[1] | |||||
| Sinopharm Group Co., Ltd. | |||
|---|---|---|---|
| Simplified Chinese | 国药控股股份有限公司 | ||
| Traditional Chinese | 國藥控股股份有限公司 | ||
| Literal meaning | Sinopharm Holding Joint-Stock Limited Company | ||
| |||
| Sinopharm Group | |||
| Simplified Chinese | 国药控股 | ||
| Traditional Chinese | 國藥控股 | ||
| Literal meaning | Sinopharm Holding | ||
| |||
| Second alternative Chinese name | |||
| Simplified Chinese | 国控股份有限公司 | ||
| Traditional Chinese | 國控股份有限公司 | ||
| |||
Its H shares were listed on the Hong Kong Stock Exchange in 2009,[2] with its IPO price of HK$16 per share. Sinopharm Group's subsidiary Sinopharm CNMC and Sinopharm Accord served as the A share counterpart of the company. However, the A share of Sinopharm Group itself was unlisted.
Sinopharm Group was ranked 829th in 2016 Forbes Global 2000 list.[3]
COVID-19 Vaccine development
The Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV,[4] the Sinopharm COVID-19 vaccine,[5] or BIBP vaccine,[5][6][7] is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. It completed Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 participants.[8] The BIBP vaccine shares similar technology with CoronaVac and Covaxin, other inactivated virus vaccines for COVID-19.[9]
Peer-reviewed results published in JAMA of Phase III trials in United Arab Emirates and Bahrain showed that the BIBP vaccine is 78.1% effective against symptomatic cases and 100% against severe cases (21 cases in vaccinated group vs. 95 cases in placebo group).[10] In December 2020, the UAE previously announced interim results showing 86% efficacy.[11] While mRNA vaccines showed higher efficacy of over 90%, those present distribution challenges for some nations as they require deep-freeze facilities and trucks. BIBP-CorV could be transported and stored at normal refrigerated temperatures.[12]
The BIBP vaccine is being used in vaccination campaigns by certain countries in Asia,[13][14][15] Africa,[16][17][18] South America,[19][20][21] and Europe.[22][23][24] Sinopharm was expected to produce one billion doses of the BIBP vaccine in 2021.[25] On 7 May 2021, the World Health Organization approved the vaccine for use in COVAX.[14][26]
